Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment
Cancer Cell · 2023-03 · 41 (3) · 620-636.e9
DOI: 10.1016/j.ccell.2023.02.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2023-03. Verfasst von John D Klement und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA; Georgia Cancer Center, Augusta, GA 30912, USA; …. Hauptthemen laut MEDLINE: Interferon Type I, Lung Neoplasms. Die Arbeit wurde bisher 131-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, CSRD VA, BLRD VA.
Abstract (Originalsprache)
The cellular and molecular mechanisms underlying tumor cell PD-L1 (tPD-L1) function in tumor immune evasion are incompletely understood. We report here that tPD-L1 does not suppress cytotoxic T lymphocyte (CTL) activity in co-cultures of tumor cells and tumor-specific CTLs and exhibits no effect on primary tumor growth. However, deleting tPD-L1 decreases lung metastasis in a CTL-dependent manner in tumor-bearing mice. Depletion of myeloid cells or knocking out PD-1 in myeloid cells (mPD-1) impairs tPD-L1 promotion of tumor lung metastasis in mice. Single-cell RNA sequencing (scRNA-seq) reveals that tPD-L1 engages mPD-1 to activate SHP2 to antagonize the type I interferon (IFN-I) and STAT1 pathway to repress Cxcl9 and impair CTL recruitment to lung metastases. Human cancer patient response to PD-1 blockade immunotherapy correlates with IFN-I response in myeloid cells. Our findings determine that tPD-L1 engages mPD-1 to activate SHP2 to suppress the IFN-I-STAT1-CXCL9 pathway to impair CTL tumor recruitment in lung metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA; Georgia Cancer Center, Augusta, GA 30912, USA; Charlie Norwood VA Medical Center, Augusta, GA 30904, USA.
- Department of Pathology, Medical College of Georgia, Augusta, GA 30912, USA.
- Georgia Cancer Center, Augusta, GA 30912, USA.
- Trinity Biomedical Sciences Institute, School of Medicine, Trinity College Dublin, Dublin, Ireland.
- Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA; Georgia Cancer Center, Augusta, GA 30912, USA; Charlie Norwood VA Medical Center, Augusta, GA 30904, USA. Electronic…
Förderung
- NCI NIH HHS
- CSRD VA
- BLRD VA
- National Institutes of Health
- U.S. Department of Veterans Affairs
Zitieren
APA
Klement, J. D., Redd, P. S., Lu, C., Merting, A. D., Poschel, D. B., Yang, D., Savage, N. M., Zhou, G., Munn, D. H., Fallon, P. G., & Liu, K. (2023). Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment. Cancer Cell, 41(3), 620-636.e9. https://doi.org/10.1016/j.ccell.2023.02.005
Vancouver
Klement JD, Redd PS, Lu C, Merting AD, Poschel DB, Yang D, et al. Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment. Cancer Cell. 2023;41(3):620-636.e9. doi:10.1016/j.ccell.2023.02.005
BibTeX
@article{Klement2023,
author = {Klement, John D and Redd, Priscilla S and Lu, Chunwan and Merting, Alyssa D and Poschel, Dakota B and Yang, Dafeng and Savage, Natasha M and Zhou, Gang and Munn, David H and Fallon, Padraic G and Liu, Kebin},
title = {Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment},
journal = {Cancer Cell},
year = {2023},
volume = {41},
number = {3},
pages = {620--636.e9},
doi = {10.1016/j.ccell.2023.02.005}
}
EUVIMED